Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...

Merck's impending Verona buyout and recent biotech deals aim to expand its pipeline and cut reliance on Keytruda sales.

Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...

Backed by an initial funding of $15 million from the National Science Foundation, the Regenerative Medicine Engine is the ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Merck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...

Three young Triangle-based medical technology companies with roots in Duke University research labs are getting major global attention from their industry. They’re among the 65 cutting-edge companies ...

Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings ...

Durham was Nvidia’s first office location outside of California. A former employee at its Durham location shares what working ...